NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high-risk head and neck squamous cell carcinoma (HNSCC).

Julie E. Bauman,Jonathan Harris,Ravindra Uppaluri,Min Yao,Robert L. Ferris,Josephine Chen,Richard C.K. Jordan,Nikhil P. Joshi,Srinivas Jujjuvaparu,Dukagjin Blakaj,Mohammad Razaq,Jawad Sheqwara,Loren K. Mell,Neilayan Sen,David A. Clump,Madhur K. Garg,Emrullah Yilmaz,Quynh-Thu Le

NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high-risk head and neck squamous cell carcinoma (HNSCC).

2019

Julie E. Bauman
Jonathan Harris
Ravindra Uppaluri
Min Yao
Robert L. Ferris
Josephine Chen
Richard C.K. Jordan
Nikhil P. Joshi
Srinivas Jujjuvaparu
Dukagjin Blakaj
Mohammad Razaq
Jawad Sheqwara
Loren K. Mell
Neilayan Sen
David A. Clump
Madhur K. Garg
Emrullah Yilmaz
Quynh-Thu Le

6023Background: Pembrolizumab, an anti-PD1 monoclonal antibody, improves survival in advanced HNSCC. Patients with pathologic high risk, HPV-negative HNSCC have a high recurrence rate despite adjuv...

Keywords:

Adjuvant
Head and neck squamous-cell carcinoma
Cohort study
Intensity-modulated radiation therapy
Oncology
Pathology
Pembrolizumab
Cisplatin
Medicine
Internal medicine
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations